Attorney Docket No.: 26230

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:

DIETRICH, et al.

Serial No.: 10/505,138

Group Art: 1615

Filed: August 19, 2004

Examiner: SILVERMAN, E.

For:

ORAL DOSAGE FORM CONTAINING A PDE 4 INHIBITOR AS AN ACTIVE

INGREDIENT AND POLYVINYLPYRROLIDON AS EXCIPIENT

REQUEST FOR

CONTINUED EXAMINATION (RCE)

TRANSMITTAL

Commissioner for Patents Box RCE P.O. Box 1450 Alexandria, VA 22313-1450

Application No.

10/505,138

Filing Date:

August 19, 2004

Title:

ORAL DOSAGE FORM CONTAINING A PDE 4 INHIBITOR AS AN ACTIVE INGREDIENT AND

POLYVINYLPYRROLIDON AS EXCIPIENT

Inventor:

DIETRICH, et al.

Group Art Unit:

1615

Examiner:

SILVERMAN, E.

Atty Docket No.:

26230

Sir:

This is a Request for Continued Examination (RCE) under 37 C.F.R § 1.114 of the aboveidentified application.

Note: 37 C.F.R. § 1.114 is effective on May 29, 2000. If the above-identified application was filed prior to May 29, 2000, applicant may wish to consider filing a continued prosecution application (CPA) under 37 C.F.R. § 1.53(d) (PTO/SB/29) instead of a RCE to be eligible for the patent term adjustment provisions of the AIPA. See Changes to Application Examination and Provisional Application and Provisional Application Practice, Final Rule 65 Fed.Reg. 50092 9Aug. 16, 2000); Interim Rule, 65 Fed. Reg. 14865 (mar. 20, 2000), 1233 Off.Gaz. Pat. Office 47 (Apr. 11, 2000), which established RCE pratice

08/30/2007 MAHMED1 00000031 10505138

01 FC:1801

Atty. Docket No.: 26230 Page 2 of 2

1.1. Submission required under 37 C.F.R. § 1.11	4	
a Previously submitted 1Consider the amendments(s)/	reply under 37 C	.F.R.§ 1.116 previously
filed on ii. Consider the arguments in the Appea		•
previously filed on 2Other		Reply Brief
 X Enclosed X Amendment X Reply — Affidavit(s)/Declaration(s) — Information Disclosure Statement — Other 	(IDS)	
2. Miscellaneous		
aSuspension of action on the above-identified 37 C.F.R. § 1.103(c) for a period of months.(Period of suspension shall not		
1.17(i) required) bOther		3
3. Fees (The RCE fee under 37 C.F.R. § 1.17(e) is required by 37 C.F.R. § 1	.114 when the RCE is	filed)
 X The Director is hereby authorized to cha overpayments, to Deposit Act. No. 14-0112. X RCE fee of \$790.00 required under 37 (is enclosed. Extension of time fee (37 C.F.R. §§ 1.13) 	C.F.R. § 1.17 (e)	fees, or credit any
iiiOther Date:	Respectfully s THE NATH LA Gary M. Nath Registration N	AW GROUP Belley 10. 26,965
THE NATH LAW GROUP 112 South West Street	Joshua B. Gol Registration N Charles D. Nie	o. 44,126
Alexandria, VA 22314	Registration N	o. 46,116
GMN:JBG:\RCE2.doc	Customer No.	343/3